]>
IRCT20180205038626N9 IRCT 2021-07-13 Rasht University of Medical Sciences The short-term outcomes of Ticagrelor versus Clopidogrel in patients with myocardial infarction Comparison the short-term outcomes of Ticagrelor versus Clopidogrel treatment in patients with myocardial infarction undergoing Percutaneous Coronary Intervention 2021-08-23 anticipated 128 Complete https://irct.ir/trial/57232 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: According to the number of 64 people in each group and 128 people in total, 4 blocks of 32 will be used. Patients based on random blocks with number of 32 people (16 people in the intervention group and 16 people in the control group) in each block and Its format will be in a sealed envelope under the supervision of the study inspector and patients will be studied daily in the study groups. The method of concealment will be by numbered envelopes, Blinding description: The two groups can be divided into the first group (receiving clopidogrel 75 mg daily and aspirin 81 mg daily) and the second group (receiving ticagrelor 90 mg twice daily and aspirin 81 mg daily) in the form of a sealed envelope to the evaluating researcher, and at the end the envelope will be opened and it will be determined that what are the treatments 1 and 2. 2 Acute myocardial infarction. Intervention 1: Control group: Clopidogrel group: patients will receive 600 mg of clopidogrel as a loading dose and then in addition to aspirin 81 mg daily, clopidogrel 75 mg daily tablet will be prescribed for 3 months. Intervention 2: Intervention group: Ticagllor group: for patients, 180 mg of ticaglor loading dose and then in addition to aspirin 81 mg daily, 90 mg ticaglor tablet twice a day and one tablet every 12 hours will be prescribed for 3 months. Yes - There is a plan to make this available What will be shared: Information on the main outcome When: Access period starts 6 months after the results are published To whom: Researchers working in academic institutions Conditions: Request to receive unidentifiable personal data or other documents Where to obtain: Dr. Salman Nikfarjam How to obtain: By email to Dr. Salman Nikfarjam Comments:
public Zahra Ahmadnia
Dr. Heshmat Hospital; Bayani St; Mosala Square; Rasht.
Rasht Iran (Islamic Republic of) 4193955588 +98 13 3361 8177 zahmadnia@gums.ac.ir Rasht University of Medical Sciences scientific Zahra Ahmadnia
Dr. Heshmat Hospital, Bayani St., Mosala Square, Rasht
Rasht Iran (Islamic Republic of) 4193955588 +98 13 3361 8177 zahmadnia@gums.ac.ir Rasht University of Medical Sciences Iran (Islamic Republic of) Age 18 years and older Chest pain that lasts more than 20 minutes and no response to nitroglycerin Patients with PCI were underwent PCI less than 12 hours from the onset of symptoms. The ST segment rises more than 1 mm in at least two or more limb leads. The ST segment is more than 2 mm high in two or more precordial leads. 18 years no limit Both Cardiogenic shock in the form of systolic blood pressure less than 90 to 60 mm Hg and did not respond to hydration therapy Thrombolysis in the last 24 hours Recent anticoagulant therapy or recent use of P2Y12 antagonist Contraindications to aspirin, clopidogrel and ticagrelor History of coronary artery bypass grafting in recent year Patient dissatisfaction I23.8 Other current complications following acute myocardial infarction Treatment - Drugs Treatment - Drugs Control group: Clopidogrel group: patients will receive 600 mg of clopidogrel as a loading dose and then in addition to aspirin 81 mg daily, clopidogrel 75 mg daily tablet will be prescribed for 3 months. Intervention group: Ticagllor group: for patients, 180 mg of ticaglor loading dose and then in addition to aspirin 81 mg daily, 90 mg ticaglor tablet twice a day and one tablet every 12 hours will be prescribed for 3 months. Thrombosis. Timepoint: 3 months later. Method of measurement: Clinical signs and laboratory tests. Stroke. Timepoint: 3 months later. Method of measurement: CT scan. Myocardial Infarction. Timepoint: 3 months later. Method of measurement: Electrocardiography, Echocardiography. Death. Timepoint: 3 months later. Method of measurement: Phone call with the patient. Actover pharmaceutical company Approved 2021-06-30 Ethics committee of Guilan University of Medical Sciences Technology & Research Vice-chancellor of University; Shahid Siadati St; Namjoo St., Rasht Rasht Guilan Iran (Islamic Republic of)